0QOK.LSE Roche Holding AG Participation
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.
Is 0QOK.LSE undervalued?
Graham numberThe Graham number of Roche Holding AG Participation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Roche Holding AG Participation fundamental analysis
No fundamental analysis for Roche Holding AG Participation yet.
Roche Holding AG Participation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Roche Holding AG Participation
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various dise…
Full company profileRoche Holding AG Participation financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Roche Holding AG Participation annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 53.3B | 56.8B | 61.5B | 58.3B | 62.8B | - | - |
| Gross Profit | 37.6B | 40.4B | 44.1B | 42.4B | 43.5B | - | - |
| Operating Income | 13.0B | 14.8B | 17.5B | 18.5B | 18.2B | - | - |
| Net Income | 8.63B | 10.5B | 13.5B | 14.3B | 13.9B | - | - |
| Balance Sheet | |||||||
| Total Assets | 76.7B | 78.5B | 83.1B | 86.1B | 92.3B | - | - |
| Total Liabilities | 50.2B | 50.9B | 50.3B | 49.8B | 67.8B | - | - |
| Shareholders' Equity | 26.4B | 27.6B | 32.7B | 36.3B | 24.5B | - | - |
| Cash & Short-term Investments | 12.0B | 13.1B | 11.9B | 12.3B | 13.0B | - | - |
| Total Debt | 15.8B | 16.1B | 13.5B | 11.1B | 17.1B | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | 18.0B | 20.0B | 22.4B | 18.6B | 21.0B | 18.4B | - |
| Capital Expenditure | 4.21B | 4.04B | 3.50B | 3.53B | 3.69B | 3.45B | - |
| Ratios | |||||||
| ROE | 32.7% | 38.0% | 41.2% | 39.3% | 56.9% | - | - |
| ROA | 11.3% | 13.4% | 16.2% | 16.6% | 15.1% | - | - |
| Net Profit Margin | 16.2% | 18.5% | 22.0% | 24.5% | 22.2% | - | - |
| Debt to Equity | 0.60x | 0.58x | 0.41x | 0.31x | 0.70x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Roche Holding AG Participation dividends
Roche Holding AG Participation has not paid dividends in the last 8 fiscal years.
Who owns Roche Holding AG Participation
- Insiders 0.00%
- Institutions 44.85%
- Public & others 55.15%
- Free float 724M
Roche Holding AG Participation company profile
- Company name
- Roche Holding AG Participation
- Ticker
- 0QOK.LSE
- ISIN
- CH0012032048
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 103,249
- Fiscal year end
- December
- Address
- Grenzacherstrasse 124, Basel, Switzerland, 4070
- Phone
- 41 61 688 88 80
- Website
- roche.com
About Roche Holding AG Participation
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
Roche Holding AG Participation management
10- Dr. Severin Schwan Ph.D.Executive Chairman · born 1967
- Dr. Thomas SchineckerGroup Chief Executive Officer · born 1975
- Dr. Alan HippeChief Financial Officer · born 1967
- Ms. Wafaa MamilliChief Digital & Technology Officer · born 1967
- Dr. Bruno EschliHead of Investor Relations
- Ms. Claudia BockstiegelGeneral Counsel · born 1964
- Dr. Nina Schwab-HautzingerHead of Group Communications · born 1975
- Ms. Maria Cristina A. WilburChief People Officer · born 1967
- Dr. Nicolas DunantHead of Group Media Relations
- Mr. Boris L. ZaitraHead of Corporate Business Development · born 1972